Kuznick Law is investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP. Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own. Kuznicki law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.